Clinical trialsCompany release

Nektar starts all three Phase 3 atopic dermatitis trials of rezpegaldesleukin

🇺🇸 Nektar Therapeutics (NKTR) · Thu 12 Nov 2026

Nektar reported Q3 2026 revenue of $9.4M, a $55.7M net loss and $952.9M in cash as its late-stage rezpegaldesleukin programme moved into full recruitment mode.

Nektar Therapeutics said on 12 November 2026 that it has launched all three Phase 3 trials in its ZENITH AD programme, which is testing rezpegaldesleukin in atopic dermatitis.

A fourth Phase 3 study, ZENITH AA, is planned in alopecia areata. The company expects that trial to begin in December.

On timelines, Nektar expects topline atopic dermatitis data in mid-2028, with a first Biologics License Application (BLA) submission targeted for 2029. A BLA is the US route for seeking marketing approval for a biological product.

For the third quarter of 2026, the company reported revenue of $9.4M and a net loss of $55.7M. Cash stood at $952.9M at the end of the period, a rise the company highlighted in its results announcement.

The source material available for this report was limited to the company's headline results and summary. It did not include trial design details, enrolment figures or financial breakdowns.

What it means for your team

  • Regulatory teams tracking atopic dermatitis biologics can note a first BLA submission is targeted for 2029, with pivotal data due mid-2028.
  • The planned ZENITH AA trial would extend rezpegaldesleukin into a second indication, alopecia areata, from December 2026.
  • Market-access analysts should treat all dates as company targets rather than confirmed regulatory milestones.

Company's press release (SEC filing): Nektar Therapeutics ↗

Article written by VigiEye from the official source (Nektar Therapeutics). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →